SCHEMBL1746641

SCHEMBL1746641

Brc1ccc(OC2Cc3ccccc3C2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 5/20 0.51
IDO1 P14902 2/20 0.47
FFAR1 O14842 1/20 0.43
TDP1 Q9NUW8 2/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 2/20 0.38
HRH1 P35367 2/20 0.37
MAPK13 O15264 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK11 Q15759 1/20 0.36
MAPK14 Q16539 1/20 0.36
SLC6A2 P23975 1/20 0.35
SLC6A3 Q01959 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
EPHX2 P34913 1/20 0.35
ADRA1A P35348 1/20 0.34
NAAA Q02083 1/20 0.34
HTR6 P50406 1/20 0.34
GAA P10253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8528204 0.80 IDO1 (0.47) SLC6A4IDO1FFAR1HRH1SLC6A2
SCHEMBL835805 0.76 EPHX2 (0.49) SLC6A4MAPTHRH1SLC6A2SLC6A3
SCHEMBL4777450 0.76 IDO1 (0.47) SLC6A4IDO1FFAR1HRH1SLC6A2
SCHEMBL8530045 0.73 IDO1 (0.44) SLC6A4IDO1FFAR1POLBHRH1
SCHEMBL19533665 0.73 SMN1; SMN2 (0.53) FFAR1TDP1POLBMAPTSMN1; SMN2
SCHEMBL9966865 0.72 PARP10 (0.53) MAPTHRH1EPHX2
SCHEMBL2414756 0.72 PARP10 (0.48) FFAR1MAPTHRH1EPHX2
SCHEMBL12100150 0.71 MAPT (0.40) MAPTEPHX2
SCHEMBL15300747 0.71 SLC6A4 (0.53) SLC6A4SLC6A2SLC6A3HTR6
SCHEMBL623713 0.71 PARP10 (0.47) MAPTEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1688138-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2006-08-09 EP disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167378-A1 Receptor Function Regulation Agent GPR119, INSR, GPR88 SLC6A4 1453/4885IDO1 4552/4885FFAR1 16/4885
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR SLC6A4 847/4885IDO1 3107/4885FFAR1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.